CELLeBRAIN

CELLeBRAIN is a South Korean private biotechnology company developing mesenchymal stem cell-mediated gene and cell therapies for neurological diseases and solid tumors. Its core approach uses allogeneic mesenchymal stem cells as carriers for therapeutic genes, aiming to improve in vivo delivery to diseased tissue while incorporating a safety gene for controllability. The company’s lead disclosed program is CB-11 for malignant brain tumors including glioblastoma, and it is also advancing CB-31 for chronic stroke. CELLeBRAIN has reported completion of an investigator-initiated trial for CB-11, received approval for an advanced regenerative clinical study in Korea, and obtained U.S. FDA orphan drug designation for CB-11 in 2026. The company appears to be positioned as a platform-focused early clinical cell and gene therapy developer rather than a commercial-stage product company.